Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 19 January 2018 | By Zachary Brennan
New generic drug applications are not winning a lot of approvals from the US Food and Drug Administration (FDA) so far in January 2018, and at least part of the reason for an increase in complete response letters (CRLs) is a new requirement from the US Pharmacopeia (USP).
Lachman Consultants' Bob Pollock, a former official in FDA’s Office of Generic Drugs, first discussed the low number of abbreviated new drug application (ANDA) approvals in January – just four approvals through 16 January – that might be linked to a new USP requirement on documentation of elemental impurities, as outlined in a draft guidance document from June 2016: “Control of Elemental Impurities in Drug Products.” The draft offers guidance on two USP chapters, USP<232> Elemental Impurities - Limits and USP<233> Elemental Impurities – Procedures and ICH Q3D Elemental Impurities.
FDA told Focus in a statement: “The January date is the end of a lengthy implementation period that was designed to give manufacturers ample time to meet the requirements. Applications that do not meet these requirements are unable to be approved and may receive a request for this information through an information request or complete response letter.”
But USP said that companies receiving CRLs for not meeting the new requirements knew they were coming for almost a decade and the implementation date of 1 January 2018 was first announced in 2015.
The Rockville, MD-based USP also explained to Focus in a statement: “The chapters establish a new approach for limiting elemental contamination in drug products. This approach replaces the 100 years old heavy metal test.”
Though USP also said that it does not think that meeting the requirements are the cause of the uptick in CRLs, USP added: “The transition to the new paradigm requires work up front. Pharmaceutical manufacturers need to assess the contribution of elemental impurities from all possible sources including raw materials, manufacturing process, packaging systems, etc. This assessment should have started a long time ago thus it is very unlikely that this could be the cause of a slower pace for ANDA approvals.
“FDA has been requiring new drug products to meet these new requirements since June 2016,” USP added.
Tags: generic drugs, CRLs
Regulatory Focus newsletters
All the biggest regulatory news and happenings.